Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Retained Earnings (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Retained Earnings data on record, last reported at -$431.1 million in Q3 2025.

  • For Q3 2025, Retained Earnings rose 4.63% year-over-year to -$431.1 million; the TTM value through Sep 2025 reached -$431.1 million, up 4.63%, while the annual FY2024 figure was -$438.6 million, 19.87% down from the prior year.
  • Retained Earnings reached -$431.1 million in Q3 2025 per GLUE's latest filing, down from -$3.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$1.4 million in Q1 2023 and bottomed at -$452.0 million in Q3 2024.
  • Average Retained Earnings over 3 years is -$285.9 million, with a median of -$365.9 million recorded in 2023.
  • The widest YoY moves for Retained Earnings: up 99.21% in 2025, down 14445.12% in 2025.
  • A 3-year view of Retained Earnings shows it stood at -$365.9 million in 2023, then decreased by 19.87% to -$438.6 million in 2024, then grew by 1.71% to -$431.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$431.1 million in Q3 2025, -$3.4 million in Q2 2025, and -$391.7 million in Q1 2025.